← Product Code FRO · K100218 # BIATAIN AGFOAM DRESSINGS-NON-ADHESIV: 5X7CM, 10X10CM, 10X20CM,15X15CM & 20X20CM (K100218) _Coloplast A/S · FRO · Feb 17, 2010 · SU · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K100218 ## Device Facts - **Applicant:** Coloplast A/S - **Product Code:** FRO - **Decision Date:** Feb 17, 2010 - **Decision:** SESE - **Submission Type:** Special - **Device Class:** Class U - **Review Panel:** SU - **Attributes:** Therapeutic ## Intended Use Biatain Ag Foam Adhesive & Non-Adhesive Dressings are indicated for use in the management of moderately to highly exuding leg ulcers and pressure sores. The dressing can also be used for 2nd degree burns, donor sites, post operative wounds and skin abrasions. Biatain Ag Foam Non-Adhesive Dressings are additionally indicated for diabetic foot ulcers. Biatain Ag Foam Cavity Dressings are indicated for deep wounds with moderate to high amounts of exudate. Biatain Ag Foam Cavity Dressings are indicated for stage II, III and IV pressure ulcers, leg ulcers, diabetic foot ulcers and first or second degree burns with significant loss of tissue. ## Device Story Biatain Ag Foam Dressings are sterile, single-use topical wound dressings designed for exuding wounds with delayed healing or infection risk. Device consists of absorbent polyurethane (PU) foam pads; some versions include a moisture-permeable PU topfilm. Foam contains silver released upon contact with wound exudate to manage bacterial presence. Available in various shapes/sizes (adhesive, non-adhesive, cavity) with thicknesses of 3mm or 4.4mm. Applied by clinicians to manage exudate and support wound healing in clinical or home settings. No active electronic components or software. ## Clinical Evidence No clinical data. Substantial equivalence supported by bench testing and biocompatibility testing. ## Technological Characteristics Polyurethane (PU) foam pads; moisture-permeable PU topfilm (except cavity version); silver-containing antimicrobial component. Dimensions: 3mm or 4.4mm thickness. Sterile, single-use. No electronic or software components. ## Predicate Devices - Contreet Adhesive Foam Dressings ([K022416](/device/K022416.md)) - Contreet Non-Adhesive Foam Dressings ([K022416](/device/K022416.md)) - Contreet Cavity Foam Dressings ([K033869](/device/K033869.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 510(k) Summary Biatain Ag Foam Dressings The assigned 510(k) number is: K100218 510(k) Owner's Name: Coloplast A/S Contact Person: Rebeka A. Stoltman Manager, Regulatory Affairs Coloplast Corp. 1601 West River Road North Minneapolis, MN 55411 Telephone: (612) 302-4997 Facsimile: (612) 287-4138 Email: usrst@coloplast.com Date Prepared: January 22, 2010 FEB 17 2010 Device Name and Classification | Trade Name: | Biatain Ag Foam Dressings | |----------------------|---------------------------------| | Common Name: | Topical Wound Dressing | | Classification: | Unclassified; 21 CFR § 878.4020 | | Classification Name: | Dressing, Wound, Drug | | Product Code: | FRO | # Manufacturer Coloplast A/S Holtedam 1 3050 Humlebaek, Denmark ﺮ ﻟﻤ Establishment Registration: 9610694 Owner/Operator: 8010144 Biatain Ag Foam Dressings - Confidential - {1}------------------------------------------------ # Device Description Biatain Ag Foam Dressings are wound dressings for exuding wounds with delayed healing due to bacteria, or where there is a risk of infection. Biatain Ag Foam Dressings consist of soft, absorbing polyurethane (PU) foam pads with a moisture-permeable PU topfilm on one side and a smooth, wound-contact surface on the other side. The foam is directly on the topfilm, except for Biatain Ag Cavity which has no topfilm. The foams contain silver, which is released upon contact with wound exudate. The dressings are available in different sizes and shapes, including squares and rectangles, with rounded corners. Biatain Ag Non-Adhesive Foam Dressings also have bevelled edges. Foam thicknesses are 3 mm or 4.4 mm. The dressings are individually-packed in a pouch. All dressings are sterile and are for single use only. # Substantial Equivalence Claim The modified Coloplast Biatain Ag Foam Dressings are substantially equivalent in performance, indications, design and materials to Coloplast's currently marketed Contreet Adhesive and Non-Adhesive Foam Dressings and Contreet Cavity Foam Dressings, which were cleared under 510(k)s K022416 & K033869, respectively. # Indications for Use Biatain Ag Foam Adhesive & Non-Adhesive Dressings are indicated for use in the management of moderately to highly exuding leg ulcers and pressure sores. The dressing can also be used for 2nd degree burns, donor sites, post operative wounds and skin abrasions. Biatain Ag Foam Non-Adhesive Dressings are additionally indicated for diabetic foot ulcers. Biatain Ag Foam Cavity Dressings are indicated for deep wounds with moderate to high amounts of exudate. Biatain Ag Foam Cavity Dressings are indicated for stage II, III and IV pressure ulcers, leg ulcers, diabetic foot ulcers and first or second degree burns with significant loss of tissue. #### Summary & Conclusions of the Nonclinical Tests Submitted Substantial equivalency is supported by bench testing compared to the predicate device and biocompatibility testing performed on the subject device. Biatain Ag Foam Dressings - Confidential - {2}------------------------------------------------ Image /page/2/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of an eagle. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 FEB 1 7 2010 Coloplast A/S % Coloplast Corporation Ms. Rebeka A. Stoltman 1601 West River Road North Minneapolis, Minnesota 55411 Re: K100218 Trade/Device Name: Biatain Ag Foam Adhesive & Non-Adhesive, & Cavity Regulatory Class: Unclassified Product Code: FRO Dated: January 22, 2010 Received: January 26, 2010 Dear Ms. Stoltman: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2 - Ms. Rebeka A. Stoltman If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.html for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/Reportal?roblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tolloffree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, Mark N. Mallonee Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indications for Use 510(k) Number (if known): Device Name: Biatain Ag Foam Adhesive & Non-Adhesive, & Cavity Biatain Ag Foam Adhesive & Non-Adhesive Dressings are indicated for use in the management of moderately to highly exuding leg ulcers and pressure sores. The dressing can also be used for 2nd degree burns, donor sites, post operative wounds and skin abrasions. Biatain Ag Foam Non-Adhesive Dressings are additionally indicated for diabetic foot ulcers. Biatain Ag Foam Cavity Dressings are indicated for deep wounds with moderate to high amounts of exudate. Biatain Ag Foam Cavity Dressings are indicated for stage II, III and IV pressure ulcers, leg ulcers, diabetic foot ulcers and first or second degree burns with significant loss of tissue. Daniel Keene for MXM Sign-Off Division of Surgical, Orthopedic, and Restorative Devic 510(k) Number K100218 Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) -0 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) --- **Source:** [https://fda.innolitics.com/device/K100218](https://fda.innolitics.com/device/K100218) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com